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Abstract
Summary The FREEDOM study and its Extension provide
long-term information about the effects of denosumab for
the treatment of postmenopausal osteoporosis. Treatment for
up to 8 years was associated with persistent reduction of bone
turnover, continued increases in bone mineral density, low
fracture incidence, and a favorable benefit/risk profile.
Introduction This study aims to report the results through year
5 of the FREEDOM Extension study, representing up to
8 years of continued denosumab treatment in postmenopausal
women with osteoporosis.
Methods Women who completed the 3-year FREEDOM
study were eligible to enter the 7-year open-label
FREEDOM Extension in which all participants are scheduled
to receive denosumab, since placebo assignment was
discontinued for ethical reasons. A total of 4550 women en-
rolled in the Extension (2343 long-term; 2207 cross-over). In
this analysis, women in the long-term and cross-over groups
received denosumab for up to 8 and 5 years, respectively.
Results Throughout the Extension, sustained reduction of
bone turnover markers (BTMs) was observed in both
groups. In the long-term group, mean bone mineral den-
sity (BMD) continued to increase significantly at each
time point measured, for cumulative 8-year gains of 18.4
and 8.3 % at the lumbar spine and total hip, respectively.
In the cross-over group, mean BMD increased significant-
ly from the Extension baseline for 5-year cumulative
gains of 13.1 and 6.2 % at the lumbar spine and total
hip, respectively. The yearly incidence of new vertebral
and nonvertebral fractures remained low in both groups.
The incidence of adverse and serious adverse events did
not increase over time. Through Extension year 5, eight
events of osteonecrosis of the jaw and two events of atyp-
ical femoral fracture were confirmed.
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Introduction
We have previously reported the results of up to 6 years of
continuous denosumab therapy in women with postmeno-
pausal osteoporosis in the 3-year FREEDOM study [1] and
its ongoing 7-year Extension [2, 3]. These data have supported
a favorable benefit/risk profile of denosumab over time. We
observed maintenance of the effect of denosumab on bone
turnover that was associated with low fracture incidence, pro-
gressive and significant increases in bone mineral density
(BMD) at all sites measured, and a well-maintained safety
profile with exposure for up to 6 years.
Bone turnover and BMD are pharmacologically modifiable
risk factors for fracture in patients with osteoporosis. Data
from the FREEDOM study demonstrated that gains in BMD
with denosumab treatment for up to 3 years were associated
with increased estimated bone strength [4], which can account
for much of the effect of denosumab in reducing fracture risk
[5]. It is of considerable scientific and clinical interest to ex-
tend these observations.
The Extension study, which will ultimately result in up to
10 years of denosumab exposure, offers an opportunity to
evaluate how safety and efficacy assessments trend over time
in an aging population of postmenopausal women with oste-
oporosis. Here, we report the year-by-year safety and efficacy
of continued denosumab therapy through the fifth year of the
Extension to the denosumab phase 3 pivotal fracture study,
FREEDOM, for a total of up to 8 years of treatment.
Materials and methods
Study design
The FREEDOM pivotal study (ClinicalTrials.gov:
NCT00089791) and the Extension designs (ClinicalTrials.gov:
NCT00523341) have been described elsewhere [1, 2] and are
summarized inOnline Resource Fig. S1. Briefly, postmenopaus-
al women aged 60–90 years with a lumbar spine or total hip
BMD T-score less than −2.5 at either site but −4.0 or greater at
both sites were eligible to enroll in FREEDOM. Participants
were randomized to receive placebo or 60 mg denosumab
(Prolia®; Amgen Inc., Thousand Oaks, CA, USA) subcutane-
ously (s.c.) every 6 months for 3 years. All participants were
instructed to take calcium (≥1 g) and vitamin D (≥400 IU) daily.
All womenwho completed the FREEDOM study (i.e., complet-
ed their 3-year visit) in either the denosumab or placebo arm, did
not discontinue investigational product, and did not miss >1
dose of investigational product were eligible to enter the
Extension where all participants are scheduled to receive open-
label 60 mg denosumab s.c. every 6 months (±1 month) with
daily calcium and vitamin D supplementation. The study is on-
going with preplanned data analyses performed at intervals as
part of continuing pharmacovigilance. The data reported here
include the first 5 years of the Extension and represent up to
8 years of denosumab exposure for womenwho received 3 years
of denosumab in FREEDOM and continued in the Extension
(long-term group), and up to 5 years of denosumab exposure for
women who received 3 years of placebo in FREEDOM and
transitioned to denosumab in the Extension (cross-over group).
The study protocol was approved by an institutional
review board or ethics committee for each institutional
site and all participants provided written informed con-
sent. Representatives of the sponsor, Amgen Inc., de-
signed the study with investigators, and statistical anal-
yses were conducted according to a prespecified statis-
tical analysis plan.
Study procedures
Study visits were scheduled at the Extension baseline (corre-
sponding to the end of the FREEDOM parent study) and ev-
ery 6 months for 7 years during the Extension.
Concentrations of serum C-terminal telopeptide of type 1
collagen (CTx; Nordic Bioscience Diagnostics A/S, Herlev,
Denmark) and procollagen type 1 N-terminal propeptide
(P1NP; Orion Diagnostica Oy, Espoo, Finland) were mea-
sured by PPD (PPD Development, Richmond, VA, USA)
and LabCorp (LabCorp Burlington, Burlington, NC, USA),
respectively, using fasting (overnight), predose morning se-
rum samples collected from a subset of women who partici-
pated in the FREEDOM bone turnover marker (BTM)
substudy and consented to continue in the Extension. At year
2 of the Extension, the protocol was amended to increase the
number of participants in the substudy. Evaluation of these
additional participants began at year 3 of the Extension.
After the publication of data from the first 2 years of the
Extension [2], additional P1NP samples from the second year
were identified in storage by the central laboratory. P1NP
levels were measured in these samples, and the data are in-
cluded in the current analysis. Consistent with previous re-
ports, undetectable values were imputed using the correspond-
ing assay’s established lower limit of quantification (CTx,
0.049 ng/mL; P1NP, 10 μg/L) [6].
BMDmeasurements were performed by dual-energy X-ray
absorptiometry (DXA) at the lumbar spine and hip in all wom-
en and at the 1/3 radius in a subset of women at the Extension
baseline and Extension years 1, 2, 3, and 5. All DXA scans
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were centrally read by BioClinica (previously known as
Synarc Inc.).
Vertebral fractures were also identified by a central facility
(BioClinica) using the Genant semiquantitative grading scale
[7] from thoracic and lumbar lateral radiographs obtained at
the Extension baseline and Extension years 2, 3, and 5.
Prevalent vertebral fractures at Extension baseline and new
vertebral fractures were defined as described previously [2].
Clinical vertebral and nonvertebral fractures required confir-
mation by diagnostic imaging or a radiologist’s report. High-
force trauma or pathological clinical vertebral and
nonvertebral fractures were excluded, as described previously
[1]. In this report, hip fractures were defined as those at the
femoral neck or intertrochanteric region; previously,
subtrochanteric fractures were also included [1–3].
Every 3 months, participants were queried about adverse
events (AEs), the occurrence of a clinical fracture, and con-
comitant medications by the study site staff. Potential events
of osteonecrosis of the jaw (ONJ) were reviewed by an inde-
pendent, blinded, external adjudication committee, as de-
scribed previously [3]. During year 3 of the Extension, an
adjudication process was initiated to review potential events
of atypical femoral fracture (AFF). Available X-ray images of
femoral fractures that occurred were reviewed by a panel at
the central radiographic vendor site (BioClinica); femoral
fractures that occurred prior to year 3 were retrospectively
reviewed. The major criteria established by the American
Society for Bone and Mineral Research 2010 Task Force for
AFF [8] were used for adjudication by this committee: fracture
location (subtrochanteric, including the femur diaphysis);
fracture type (non-comminuted, simple transverse, or short
oblique); no or minimal trauma; and the absence of any evi-
dence of malignancy, prosthesis, pins, or other hardware at or
near the fracture site prior to the fracture event. A finding of
indeterminate was not permitted.
Statistical methods
The primary objective of the Extension is to evaluate the safe-
ty and tolerability of denosumab. Key secondary objectives
include evaluation of the effects on BTMs and BMD, and the
incidence of new vertebral and nonvertebral fractures. The
protocol specifies that all endpoints will be analyzed accord-
ing to the original randomized treatment group assignments in
FREEDOM.
Safety analyses included participants who received ≥1 dose
of investigational product in the Extension and were based on
the original randomized treatment assignments in
FREEDOM. Therefore, in the current safety analyses, seven
of the original placebo-group subjects who received one in-
correct dose of denosumab in FREEDOM and were previous-
ly summarized in the denosumab group [1] were included in
the FREEDOM placebo group. For consistency with previous
reports of the FREEDOM Extension data [2, 3], the Medical
Dictionary for Regulatory Activities v13.0 was used to code
and report AEs for this publication. Descriptive analyses of
AEs and serious adverse events (SAEs) included exposure-
adjusted subject incidence rates. Within each yearly or cumu-
lative interval, the exposure-adjusted subject incidence was
calculated as the number of subjects who experienced a par-
ticular AE divided by the total exposure time within the inter-
val. A subject who experienced repeated episodes of the same
AE within the yearly or cumulative interval of interest was
counted only once for that interval. For example, a subject
who experienced a common cold during years 1 and 3 was
counted once in year 1 and once in year 3 for those yearly
intervals, but only once for the 5-year cumulative interval.
Analyses of BTMs included participants who received ≥1
dose of investigational product in the Extension and had ob-
served values at the time points of interest. Results are pre-
sented as medians and interquartile ranges. Analyses of BMD
percentage change from either FREEDOM or Extension base-
line required observed values at the respective baseline and
the time points of interest, and were conducted using a repeat-
ed measures model as described previously [2]. Least squares
means with 95 % confidence intervals were calculated and
reported. In addition, BMD gains between consecutive DXA
evaluations during the Extension were assessed.
Cumulative and yearly crude subject incidence of new ver-
tebral fractures and Kaplan-Meier estimates of cumulative and
yearly subject incidence of nonvertebral fractures were
calculated.
Fracture and safety data from the FREEDOM parent study
have been summarized to allow comparison with the
Extension results. For BTMs and BMD, only data from wom-
en enrolled in the Extension are presented.
Results
Of the 7808 women enrolled in the FREEDOM study, 5928
(76 %) were eligible for enrollment in the Extension, and of
these, 4550 (77 %) enrolled (2343 long-term, 2207 cross-
over) (Fig. 1). Of the women who entered the Extension,
66 % in each group completed year 5 totaling 3004 partici-
pants. The percentage of women who discontinued the study
and the reasons for discontinuation were similar between the
two groups (Fig. 1). The demographics of the two groupswere
balanced at the start of the Extension [2]; Online Resource
Table S1 summarizes characteristics for the long-term and
cross-over groups at both the FREEDOM and Extension base-
lines. The mean (standard deviation) age for the women who
completed year 5 of the Extension was 79.0 (4.7)years. Since
these two groups have different durations of exposure to
denosumab, the results from each group are described sepa-
rately below.
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Long-term group
BTMs and BMD
Following administration of denosumab at the beginning of
the Extension, prompt decreases in serum CTx and P1NP
concentrations were observed at month 1, followed by a char-
acteristic attenuation in the degree of reduction of remodeling
through month 6, consistent with the FREEDOMparent study
(Fig. 2). Through year 5 of the Extension, representing up to
8 years of therapy, denosumab treatment resulted in sustained
reduction of serum CTx and P1NP levels.
During the Extension, mean percentage changes from
FREEDOM baseline in lumbar spine, total hip, and femoral
neck BMD at each time point were significantly greater than
those observed at the previous time point (Online Resource
Table S2). Mean percentage changes in BMD from
FREEDOM through Extension year 5, totaling up to 8 years
of treatment, were increases of 18.4 % at the lumbar spine,
8.3 % at the total hip, 7.8 % at the femoral neck, and 3.5 % at
the 1/3 radius (all p<0.05) (Fig. 3).
Fractures
Among subjects who entered the Extension and had at least
one subsequent X-ray assessment for new vertebral fracture,
116 women (5.5 %) in the long-term group had at least one
new vertebral fracture by Extension year 5. Throughout the
Extension, the annualized subject incidence of new vertebral
fractures remained low (1.5, 1.3, and 1.3 % during years 4/5,
6, and 7/8 of denosumab treatment, respectively) (Fig. 4a and
Online Resource Fig. S2). By Extension year 5, 133 women
(6.6 %) had at least one nonvertebral fracture, and the yearly
subject incidence remained low (1.5, 1.2, 1.8, 1.6, and 0.7 %
during years 4, 5, 6, 7, and 8 of denosumab treatment, respec-
tively) (Fig. 4b and Online Resource Fig. S2). Through year 5
of the Extension, the most common nonvertebral fracture sites
in the long-term group were wrist (n=57), rib (n=17), hip
(femoral neck or intertrochanteric) (n=13), and ankle (n=
12) (n is the number of affected women). The cumulative
subject incidence of hip fractures during years 1 through 5
of the Extension was 0.7 %; the annualized incidence of hip
fractures during Extension year 5 (totaling up to 8 years of
denosumab treatment), when the mean age of the group was
79.0 years, was 0.2 %.
AEs and SAEs
The yearly exposure-adjusted subject incidence for all AEs
during the Extension in the long-term group was similar to
or lower than in the active treatment group during FREEDOM
(Table 1). The yearly rates for malignancy and serious infec-
tions as well as for other AEs of interest per 100 subject-years
showed no trend toward increase over time (Table 1). For AEs
and SAEs where events were <0.1 per 100 subjects-years,
yearly rates expressed per 10,000 subject-years are shown in
Table 2. The cumulative exposure-adjusted subject incidence
rates for all AEs, SAEs, and fatal AEs in the long-term group
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Fig. 1 Disposition of all
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during the Extension were 100.8, 10.7, and 0.8 per 100 sub-
ject-years, respectively (Online Resource Tables S3 and S4).
During 8 years of denosumab treatment, four
subtrochanteric/diaphyseal femoral fractures occurred in
the long-term group; of these, one was adjudicated as
consistent with atypical diaphyseal femoral fracture. It
occurred in Extension year 4 after the participant re-
ceived her 14th dose of denosumab. Initial treatment
included internal fixation with an intramedullary nail.
The participant developed hardware failure in the form
of broken distal locking screws, which was detected
6 weeks after intramedullary rod placement. Union was
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delayed but progressed after surgical revision was per-
formed, approximately 20 months after detection of the
broken screws . The par t ic ipant has cont inued
denosumab treatment and remained in the study. There
were no cases of AFF in the long-term group during
year 5.
Through year 5 of the Extension, five oral events have
been adjudicated as consistent with ONJ in the long-term
group. Of the four previously reported cases [3], one
event previously reported as resolved is ongoing at the
time of this report. The fifth event occurred in the fourth
year of the Extension, after the participant received her
13th dose of denosumab; denosumab was discontinued
and the event has resolved. No additional ONJ events
were reported during year 5.
Cross-over group
BTMs and BMD
In the cross-over group, the median concentrations of se-
rum CTx and P1NP were rapidly reduced after the initial
administration of denosumab (day 10 and month 6 of the
Extension, respectively) and were similar to those ob-
served in the denosumab group in the FREEDOM parent
study (Fig. 2). The reductions in both markers were also
sustained through 5 years of denosumab treatment and,
over time, the bone turnover profiles were consistent with
the long-term group during their first 5 years of
denosumab exposure.
BMD increased rapidly in the cross-over group during
the first year of denosumab treatment, and measurements
at the lumbar spine, total hip, and femoral neck continued
to increase significantly at each time point measured com-
pared to the previous time point through 5 years of treat-
ment (Online Resource Table S2). The mean percentage
changes in BMD from Extension baseline were 13.1 % at
the lumbar spine, 6.2 % at the total hip, 5.7 % at the
femoral neck, and 1.5 % at the 1/3 radius (all p<0.05)
(Fig. 3). These values largely replicated those observed
in the long-term group after 5 years of denosumab expo-
sure, which were 13.7 % at the lumbar spine, 7.0 % at the
total hip, 6.1 % at the femoral neck, and 2.3 % at the 1/3
radius (all p<0.05) [2].
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Fig. 4 Incidence of nonvertebral
and new vertebral fractures during
FREEDOM and the FREEDOM
Extension. The yearly incidence
of new vertebral and nonvertebral
fractures in the long-term (a, b)
and cross-over (c, d) groups are
shown. For new vertebral
fractures, percentages are crude
incidence; lateral radiographs
(lumbar and thoracic) were not
obtained at Extension years 1 and
4 (long-term denosumab
treatment years 4 and 7);
n=number of women with ≥1
fracture; N=number of women
with a spine X-ray evaluation
during the time period of interest.
aAnnualized incidence (2-year
incidence/2). For nonvertebral
fractures, percentages are Kaplan-
Meier estimates; n=number of
women with ≥1 fracture;
N=number of women who were
still on study at the beginning of
each period
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Fractures
During the fifth year of the Extension, totaling up to
5 years of denosumab treatment, fracture rates remained
low in the cross-over group; 110 women in the cross-over
group (5.5 %) had at least one new vertebral fracture.
These low rates are similar to those observed during the
first 5 years of denosumab treatment in the long-term
group (4.0 %). In addition, the annualized subject inci-
dence of new vertebral fracture remained low after the
initiation of denosumab (0.9, 1.6, and 1.8 % during years
1/2, 3, and 4/5 of denosumab treatment, respectively)
(Fig. 4c and Online Resource Fig. S2). One hundred and
seventy-five women (9.2 %) had at least one nonvertebral
fracture through year 5 of the Extension, consistent with
the cumulative subject incidence observed over the first
5 years of denosumab treatment in the long-term group
(7.9 %). Likewise, the yearly subject incidence remained
low (2.5, 2.0, 2.6, 1.2, and 1.4 % during years 1, 2, 3, 4,
and 5 of denosumab treatment, respectively) (Fig. 4d and
Online Resource Fig. S2). Through year 5 of the
Extension, the most common nonvertebral fracture sites
in the cross-over group were wrist (n=76), hip (femoral
neck or intertrochanteric) (n=22), ankle (n=19), humerus
Table 1 Yearly exposure-adjusted subject incidence of adverse events per 100 subject-years for long-term denosumab participants
FREEDOM (years 1–3)
Denosumab
FREEDOM Extension (years 1–5)
Long-term denosumab
Denosumab exposure Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
N = 3879 3682 3487 2343 2244 2067 1867 1742
All adverse events 188.5 154.9 131.6 134.8 116.9 114.2 120.8 106.3
Infections 37.7 31.9 31.0 30.3 26.8 27.5 28.9 26.9
Malignancies 1.8 1.5 2.2 2.0 2.4 2.0 2.7 1.7
Eczema 1.6 1.1 0.9 1.0 1.3 1.0 0.7 0.7
Hypocalcemia 0 0 0 0 <0.1 0 <0.1 0
Pancreatitis <0.1 <0.1 <0.1 0 <0.1 0.2 <0.1 0.1
Serious adverse events 11.8 11.2 12.0 10.8 13.0 12.3 15.4 11.3
Infections 1.5 1.6 1.6 1.3 1.2 1.7 2.4 1.2
Cellulitis or erysipelas 0.1 <0.1 0.2 <0.1 <0.1 0.1 0 0.2
Fatal adverse events 0.6 0.6 0.7 0.4 0.8 0.9 1.3 0.7
Osteonecrosis of the jaw 0 0 0 0 0 0.2 <0.1 0
Atypical femoral fracture 0 0 0 0 0 0 <0.1 0
Analyses were based on the original randomized treatments in FREEDOM. All adverse and serious adverse events were coded using MedDRAv13.0
N number of womenwho received ≥1 dose of investigational product in FREEDOMor the Extension andwere on study at the beginning of the yearly interval
Table 2 Yearly exposure-adjusted subject incidence of adverse events per 10,000 subject-years for long-term denosumab participants where events of
interest were <0.1 per 100 subject-years
FREEDOM (years 1–3)
Denosumab
FREEDOM Extension (years 1–5)
Long-term denosumab
Denosumab exposure Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
N = 3879 3682 3487 2343 2244 2067 1867 1742
Hypocalcemia 0 0 0 0 9.2 0 5.6 0
Pancreatitis 5.3 5.6 8.7 0 4.6 15.6 5.6 12.2
Serious cellulitis or erysipelas 10.6 2.8 23.3 8.7 4.6 10.4 0 18.3
Osteonecrosis of the jaw 0 0 0 0 0 20.8 5.6 0
Atypical femoral fracture 0 0 0 0 0 0 5.6 0
Analyses were based on the original randomized treatments in FREEDOM. All adverse and serious adverse events were coded using MedDRAv13.0
N number of women who received ≥1 dose of investigational product in FREEDOM or the Extension and were on study at the beginning of the yearly
interval
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(n=15), and rib (n=14) (n is the number of affected wom-
en). The cumulative subject incidence of hip fractures
during years 1 through 5 of the Extension was 1.1 %.
AEs and SAEs
Overall, the AE rates in the cross-over group confirmed those
previously reported for the corresponding time period in the
long-term group [2]. The yearly exposure-adjusted subject
incidence for all AEs in the cross-over group during the
Extension was similar to or lower than that of the placebo
group during FREEDOM (Table 3). The yearly rates per 100
subject-years showed no increase over time. For AEs and
SAEs where events were <0.1 per 100 subjects-years, yearly
rates expressed per 10,000 subject-years are shown in Table 4.
The cumulative exposure-adjusted subject incidence rates of
all AEs, SAEs, and fatal AEs in the cross-over group during
the Extension were 99.7, 10.2, and 0.7 per 100 subject-years,
respectively (Online Resource Tables S3 and S4).
During 5 years of denosumab treatment, three diaphyseal
femoral fractures occurred in the cross-over group. Of these,
one fracture was adjudicated as consistent with AFF, as pre-
viously reported [3]. There were no reports of AFF during
year 5 of the Extension in the cross-over group.
Through year 5 of the Extension, three oral events have
been adjudicated as consistent with ONJ in the cross-over
group. Two of these events resolved as previously reported
[3]. The third event occurred in year 4 of the Extension, after
the participant received her eighth dose of denosumab. The
participant discontinued the study. Hence, the outcome of the
case is unknown. There were no ONJ cases during Extension
year 5.
Discussion
The FREEDOM Extension is a large ongoing study to evalu-
ate the long-term benefit/risk of denosumab treatment for os-
teoporosis. These data address important considerations in
interpreting the safety and efficacy of a new therapeutic class
of treatment for long-term use in a chronic condition in an
aging population. The study design incorporates a long-term
treatment group to characterize the effects of up to 10 years of
exposure, and a cross-over treatment cohort to further charac-
terize and confirm assessments of efficacy and safety findings
from extended denosumab administration, with a 3-year delay.
The primary purpose of this study is to evaluate the long-
term safety of denosumab. The year-by-year results for
FREEDOM and its Extension, presented here for the first
time, demonstrate that the safety profile of denosumab has
remained consistent over 8 years of treatment. Notably, in this
aging population, the subject incidence of AEs such as serious
infection, cellulitis, and eczema remained low with no evi-
dence of increased frequency through 8 years of denosumab
exposure, as did infrequent events. Bone safety events of ONJ
and AFF were observed, and the rates remained low. Through
Table 3 Yearly exposure-adjusted subject incidence of adverse events per 100 subject-years for cross-over denosumab participants
FREEDOM (years 1–3)
Placebo
FREEDOM Extension (years 1–5)
Cross-over denosumaba
Denosumab exposure – – – Year 1 Year 2 Year 3 Year 4 Year 5
N = 3883 3687 3454 2206 2105 1965 1756 1646
All adverse events 189.5 156.3 132.8 132.1 112.3 109.8 122.5 100.1
Infections 38.6 33.9 31.7 30.8 27.5 26.0 27.6 24.7
Malignancies 1.8 1.6 1.5 1.9 1.6 2.1 2.6 2.1
Eczema 0.8 0.5 0.6 1.0 0.9 1.1 1.2 1.0
Hypocalcemia <0.1 0 <0.1 0.2 <0.1 0 <0.1 0.2
Pancreatitis <0.1 <0.1 0 <0.1 0 <0.1 0 0
Serious adverse events 11.7 11.9 10.8 12.4 12.2 12.3 12.3 12.3
Infections 1.1 1.4 1.4 1.6 1.5 1.1 1.6 1.3
Cellulitis or erysipelas 0 0 <0.1 0 <0.1 0 <0.1 0.1
Fatal adverse events 0.8 0.8 1.0 0.9 0.6 0.5 0.7 0.8
Osteonecrosis of the jaw 0 0 0 0 0.1 0 <0.1 0
Atypical femoral fracture 0 0 0 0 0 <0.1 0 0
Analyses were based on the original randomized treatments in FREEDOM. All adverse and serious adverse events were coded using MedDRAv13.0
N number of women who received ≥1 dose of investigational product in FREEDOM or the Extension and were on study at the beginning of the yearly
interval
a One cross-over subject did not receive investigational product in the Extension and therefore was excluded from the safety analysis
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Extension year 5, eight events of ONJ and two events of AFF
were confirmed by adjudicators. The cumulative exposure-
adjusted subject incidence rates during the Extension (years
1–5), including both the long-term and cross-over groups,
were 4.2 per 10,000 subject-years for ONJ and 1.0 per 10,
000 subject-years for AFF.
Denosumab’s mechanism of action, which prevents the
generation, proliferation, and survival of osteoclasts, results
in a marked reduction of bone resorption during most of the
dosing period, though the pharmacodynamic profile shows
some release of inhibition toward the end of the dosing inter-
val. The BTMs described in the study were measured at the
end of the dosing intervals when the effect of denosumab has
been shown to wane, and undetectable values were imputed at
the lower limit of detection, which may overestimate levels.
Thus, reported levels of serum CTx may not fully reflect the
maximal antiresorptive effect that occurs during much of the
dosing interval [6]. Bone formation markers also are reduced.
This turnover pattern was associated with a finding that is
different from other antiresorptive therapies to date, namely
a continuous progressive and significant increase in BMD. In
both groups, markers of bone resorption remained low and
BMD at the lumbar spine, total hip, and femoral neck contin-
ued to increase at each time point measured over the course of
the Extension. BMD also continued to increase at the 1/3
radius in both the long-term and cross-over groups. These
gains are noteworthy, as the radius has been shown to be
minimally responsive to most osteoporosis treatments [9–11].
The overall effect of 5 years of denosumab treatment on
BMD was similar between the two groups. Furthermore, the
effects on BMD in the long-term groupwere consistent with the
8-year gains reported in the lumbar spine and proximal femur in
the phase 2 denosumab dose-ranging extension study [12]. The
clinical significance of the BMD increases is supported by the
associated sustained effects on fracture rates in both the long-
term and cross-over groups during the Extension. The exact
mechanism(s) underlying this pattern of BMD increases
throughout the skeleton remains to be fully elucidated [3].
Hypotheses based on previous observations may help to
explain the progressive gains in BMD without apparent ther-
apeutic plateau and the low fracture incidence over time. As is
known to occur with other antiresorptives, the early increase
in BMD is at least partly due to the closing of the remodeling
space and the subsequent secondary mineralization of bone
apposed during the formation phase of existing remodeling
units. However, such effects would be self-limited, and resul-
tant BMD and mass gains would be expected to approach a
plateau after 2 to 4 years [13, 14]. With denosumab, this pla-
teau in BMD has not been observed. Denosumab has been
shown to decrease cortical porosity [15]. Furthermore, tran-
sient increases in parathyroid hormone following dosing have
been documented [16]. Most recently, modeling-based bone
formation was observed in the femoral neck of ovariectomized
cynomolgus monkeys treated with denosumab for 16 months
at a dose that fully inhibited remodeling [17]. That observa-
tion, which remains to be reproduced in humans, raises the
possibility that denosumab does not prevent modeling and that
ongoing modeling-based bone formation in a setting of max-
imally reduced resorption could contribute to the continued
increases in bone mass. This is of particular clinical relevance
because gains in BMD and mass, resulting from modeling in
areas of high biomechanical stresses, could improve bone
strength and reduce fracture risk [18, 19].
A significant limitation of this study is the lack of an on-
going placebo group, and these analyses cannot substitute for
the results of a randomized placebo-controlled study. The pla-
cebo phase was terminated with the end of the core trial for
ethical reasons. The previously reported virtual twinmodeling
approach addressed this limitation [2, 3], as does the compar-
ison of baseline characteristics of the Extension participants
Table 4 Yearly exposure-adjusted subject incidence of adverse events per 10,000 subject-years for cross-over denosumab participants where events of
interest were <0.1 per 100 subject-years
FREEDOM (years 1–3)
Placebo
FREEDOM Extension (years 1–5)
Cross-over denosumaba
Denosumab exposure – – – Year 1 Year 2 Year 3 Year 4 Year 5
N = 3883 3687 3454 2206 2105 1965 1756 1646
Hypocalcemia 5.3 0 3.0 23.2 4.9 0 5.9 19.1
Pancreatitis 5.3 2.8 0 4.6 0 5.5 0 0
Serious cellulitis or erysipelas 0 0 3.0 0 4.9 0 5.9 12.7
Osteonecrosis of the jaw 0 0 0 0 9.8 0 5.9 0
Atypical femoral fracture 0 0 0 0 0 5.5 0 0
Analyses were based on the original randomized treatments in FREEDOM. All adverse and serious adverse events were coded using MedDRAv13.0
N number of women who received ≥1 dose of investigational product in FREEDOM or the Extension and were on study at the beginning of the yearly
interval
a One cross-over subject did not receive investigational product in the Extension and therefore was excluded from the safety analysis
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with the original study population. A per-protocol, post-hoc
analysis of the rates of nonvertebral fractures through
Extension year 4, limited to individuals who entered the
Extension, has also been performed and is the subject of a
separate report [20].
Subject attrition is also an important consideration in inter-
pretation of safety and efficacy results from long-term follow-
up studies. A series of analyses were recently presented that
compared FREEDOM and Extension populations at baseline
and in the Extension to assess potential selection bias that
might influence long-term treatment fracture outcomes [21].
Increasing age and incident fracture were not deterrents to
continued study participation, suggesting that safety and effi-
cacy outcomes reflected denosumab treatment effect.
In conclusion, data from this ongoing long-term Extension
study showed that continued treatment of women with post-
menopausal osteoporosis with denosumab for up to 8 years
resulted in sustained reduction of bone turnover, continued
gains in BMD at each time point measured, and continued
low yearly fracture incidence. Furthermore, the women in
the cross-over group responded to 5 years of denosumab treat-
ment similarly to the women in the long-term group during
their first 5 years of denosumab treatment. The overall safety
profile of denosumab in this ongoing study remains consistent
over time, indicating a favorable balance between benefit and
risk through 8 years of treatment.
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